Literature DB >> 3611201

Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population.

B S Leung, A H Potter.   

Abstract

The mammary cancer cell line CAMA-1 synchronized at the G1/S boundary by thymidine block or at the G1/M boundary by nocodazole was used to evaluate 1) the sensitivity of a specific cell cycle phase or phases to 17 beta-estradiol (E2), 2) the effect of E2 on cell cycle kinetics, and 3) the resultant E2 effect on cell proliferation. In synchronized G1/S cells, E2-induced 3H-thymidine uptake, which indicated a newly formed S population, was observed only when E2 was added during, but not after, thymidine synchronization. Synchronized G2/M cells, enriched by Percoll gradient centrifugation to approximately 90% mitotic cells, responded to E2 added immediately following selection; the total E2-treated population traversed the cycle faster and reached S phase approximately 4 hr earlier than cells not exposed to E2. When E2 was added during the last hour of synchronization (ie, at late G2 or G2/M), or for 1 hr during mitotic cell enrichment, a mixed response occurred: a small portion had an accelerated G1 exit, while the majority of cells behaved the same as controls not incubated with E2. When E2 addition was delayed until 2 hr, 7 hr, or 12 hr following cell selection, to allow many early G1 phase cells to miss E2 exposure, the response to E2 was again mixed. When E2 was added during the 16 hr of nocodazole synchronization, when cells were largely at S or possibly at early G2, it inhibited entry into S phase. The E2-induced increase or decrease of S phase cells in the nocodazole experiments also showed corresponding changes in mitotic index and cell number. These results showed that the early G1 phase and possibly the G2/M phase are sensitive to E2 stimulation, late G1, G1/S, or G2 are refractory; the E2 stimualtion of cell proliferation is due primarily to an increased proportion of G1 cells that traverse the cell cycle and a shortened G1 period, E2 does not facilitate faster cell division; and estrogen-induced cell proliferation or G1/S transition occurs only when very early G1 phase cells are exposed to estrogen. These results are consistent with the constant transition probability hypothesis, that is, E2 alters the probability of cells entering into DNA synthesis without significantly affecting the duration of other cell cycle phases. Results from this study provide new information for further studies aimed at elucidating E2-modulated G1 events related to tumor growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3611201     DOI: 10.1002/jcb.240340307

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

2.  Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

Authors:  J S Foster; D C Henley; A Bukovsky; P Seth; J Wimalasena
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

Review 4.  Estrogen and progestin regulation of cell cycle progression.

Authors:  R L Sutherland; O W Prall; C K Watts; E A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

5.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

Authors:  E A Musgrove; J A Hamilton; C S Lee; K J Sweeney; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

Review 6.  Emerging therapies for breast cancer.

Authors:  Xichun Hu; Wei Huang; Minhao Fan
Journal:  J Hematol Oncol       Date:  2017-04-28       Impact factor: 17.388

7.  Functional analysis of familial Asp67Glu and Thr1051Ser BRCA1 mutations in breast/ovarian carcinogenesis.

Authors:  Malinee Pongsavee; Pimpicha Patmasiriwat; Grady F Saunders
Journal:  Int J Mol Sci       Date:  2009-09-24       Impact factor: 6.208

8.  Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation.

Authors:  Johan Hartman; Eric W-F Lam; Jan-Ake Gustafsson; Anders Ström
Journal:  Breast Cancer Res       Date:  2009-11-05       Impact factor: 6.466

9.  Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen.

Authors:  A J Stewart; B R Westley; F E May
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.